Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.42 |
| ▸ | USP14 | P54578 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171314 | 0.93 | PPARG (0.42) | PPARGUSP14PTGESTHRATHRB | |
| SCHEMBL333879 | 0.93 | PPARG (0.41) | PPARGUSP14PPARAKDM4EHIF1A | |
| SCHEMBL333656 | 0.92 | PPARG (0.43) | PPARGUSP14PPARATHRATHRB | |
| SCHEMBL333611 | 0.92 | PPARG (0.47) | PPARGUSP14PPARAPTGESKDM4E | |
| SCHEMBL10076916 | 0.91 | PPARG (0.47) | PPARGUSP14PPARATHRBKDM4E | |
| SCHEMBL333835 | 0.89 | KDM4E (0.47) | USP14FFAR1PTGESTHRBKDM4E | |
| SCHEMBL1407175 | 0.89 | PPARG (0.39) | PPARGUSP14PPARAFFAR1THRA | |
| SCHEMBL334342 | 0.86 | USP14 (0.45) | PPARGUSP14PPARAFFAR1PTGES | |
| SCHEMBL333774 | 0.86 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL333497 | 0.85 | USP14 (0.44) | PPARGUSP14PPARAFFAR1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PPARG 2451/4885USP14 3873/4885PPARA 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.